339 related articles for article (PubMed ID: 15747376)
21. Icaritin induces cellular senescence by accumulating the ROS production and regulation of the Jak2/Stat3/p21 pathway in imatinib-resistant, chronic myeloid leukemia cells.
Zhu S; Xing C; Zhang G; Peng H; Wang Z
Am J Transl Res; 2021; 13(8):8860-8872. PubMed ID: 34540000
[TBL] [Abstract][Full Text] [Related]
22. Chronic Myeloid Leukemia: A Model Disease of the Past, Present and Future.
Minciacchi VR; Kumar R; Krause DS
Cells; 2021 Jan; 10(1):. PubMed ID: 33435150
[TBL] [Abstract][Full Text] [Related]
23. Myeloid Leukemias: A Glance at Middle Eastern Centers.
Khaled SA; Nabih O; Abdel Aziz NM; Mahran DG
J Blood Med; 2019; 10():425-433. PubMed ID: 31908557
[TBL] [Abstract][Full Text] [Related]
24. Wasabi Compound 6-(Methylsulfinyl) Hexyl Isothiocyanate Induces Cell Death with Coexisting Mitotic Arrest and Autophagy in Human Chronic Myelogenous Leukemia K562 Cells.
Wu KM; Liao HF; Chi CW; Kou YR; Chen YJ
Biomolecules; 2019 Nov; 9(12):. PubMed ID: 31771225
[TBL] [Abstract][Full Text] [Related]
25. New approaches to molecular monitoring in CML (and other diseases).
Radich J; Yeung C; Wu D
Blood; 2019 Nov; 134(19):1578-1584. PubMed ID: 31533919
[TBL] [Abstract][Full Text] [Related]
26. Molecular Mechanisms of Resistance to Tyrosine Kinase Inhibitors.
Yaghmaie M; Yeung CC
Curr Hematol Malig Rep; 2019 Oct; 14(5):395-404. PubMed ID: 31463864
[TBL] [Abstract][Full Text] [Related]
27. Impact of Additional Chromosomal Aberrations on the Disease Progression of Chronic Myelogenous Leukemia.
Krishna Chandran R; Geetha N; Sakthivel KM; Suresh Kumar R; Jagathnath Krishna KMN; Sreedharan H
Front Oncol; 2019; 9():88. PubMed ID: 30891424
[TBL] [Abstract][Full Text] [Related]
28. A validated UPLC-MS/MS method for simultaneous determination of imatinib, dasatinib and nilotinib in human plasma.
Zeng J; Cai HL; Jiang ZP; Wang Q; Zhu Y; Xu P; Zhao XL
J Pharm Anal; 2017 Dec; 7(6):374-380. PubMed ID: 29404062
[TBL] [Abstract][Full Text] [Related]
29. Functional screen analysis reveals miR-3142 as central regulator in chemoresistance and proliferation through activation of the PTEN-AKT pathway in CML.
Zhao L; Shan Y; Liu B; Li Y; Jia L
Cell Death Dis; 2017 May; 8(5):e2830. PubMed ID: 28542127
[TBL] [Abstract][Full Text] [Related]
30. Tyrosine kinase inhibitors in chronic myeloid leukaemia: which, when, for whom?
Rosti G; Castagnetti F; Gugliotta G; Baccarani M
Nat Rev Clin Oncol; 2017 Mar; 14(3):141-154. PubMed ID: 27752053
[TBL] [Abstract][Full Text] [Related]
31. Molecular monitoring of chronic myeloid leukemia: present and future.
Yeung CC; Egan D; Radich JP
Expert Rev Mol Diagn; 2016 Oct; 16(10):1083-1091. PubMed ID: 27552202
[TBL] [Abstract][Full Text] [Related]
32. New Developments in Chronic Myeloid Leukemia: Implications for Therapy.
Tabarestani S; Movafagh A
Iran J Cancer Prev; 2016 Feb; 9(1):e3961. PubMed ID: 27366312
[TBL] [Abstract][Full Text] [Related]
33. New Methodologies in the Molecular Monitoring of CML.
Yeung CC; Egan D; Radich J
Curr Hematol Malig Rep; 2016 Apr; 11(2):94-101. PubMed ID: 26946301
[TBL] [Abstract][Full Text] [Related]
34. Overexpression of RPS27a contributes to enhanced chemoresistance of CML cells to imatinib by the transactivated STAT3.
Wang H; Xie B; Kong Y; Tao Y; Yang G; Gao M; Xu H; Zhan F; Shi J; Zhang Y; Wu X
Oncotarget; 2016 Apr; 7(14):18638-50. PubMed ID: 26942564
[TBL] [Abstract][Full Text] [Related]
35. Secondary mutations as mediators of resistance to targeted therapy in leukemia.
Daver N; Cortes J; Ravandi F; Patel KP; Burger JA; Konopleva M; Kantarjian H
Blood; 2015 May; 125(21):3236-45. PubMed ID: 25795921
[TBL] [Abstract][Full Text] [Related]
36. Practical management of patients with chronic myeloid leukemia who develop tyrosine kinase inhibitor-resistant BCR-ABL1 mutations.
Ai J; Tiu RV
Ther Adv Hematol; 2014 Aug; 5(4):107-20. PubMed ID: 25360237
[TBL] [Abstract][Full Text] [Related]
37. Patients with Philadelphia-positive leukemia with BCR-ABL kinase mutations before allogeneic transplantation predominantly relapse with the same mutation.
Egan DN; Beppu L; Radich JP
Biol Blood Marrow Transplant; 2015 Jan; 21(1):184-9. PubMed ID: 25300870
[TBL] [Abstract][Full Text] [Related]
38. Inhibition of 32Dp210 cells harboring T315I mutation by a novel derivative of emodin correlates with down-regulation of BCR-ABL and its downstream signaling pathways.
Li J; Chen Y; Chen B; Chen C; Qiu B; Zheng Z; Zheng J; Liu T; Wang W; Hu J
J Cancer Res Clin Oncol; 2015 Feb; 141(2):283-93. PubMed ID: 25217883
[TBL] [Abstract][Full Text] [Related]
39. Response to tyrosine kinase inhibitors in chronic myeloid leukemia: experience from a west Asian developing country.
Ali MD; Badi AI; Al-Zebari SS; Al-Allawi NA
Int J Hematol; 2014 Sep; 100(3):274-80. PubMed ID: 25085252
[TBL] [Abstract][Full Text] [Related]
40. Kinase-independent mechanisms of resistance of leukemia stem cells to tyrosine kinase inhibitors.
Ichim CV
Stem Cells Transl Med; 2014 Apr; 3(4):405-15. PubMed ID: 24598782
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
